Hemostemix Announces $2,725,982 Update to Second Closing
Hemostemix has announced an update to its second closing, adding a $50,000 subscription to reach total gross proceeds of $2,725,981.77 through the issuance of 54,519,635 Units. The company paid finder fees of approximately $28,820.64 and issued 576,413 finder's options exercisable at $0.05 per Common Share within 24 months.
The offering includes participation from company directors, constituting a related party transaction under MI 61-101. The company is exempt from formal valuation and minority shareholder approval requirements as the transaction value does not exceed 25% of market capitalization. All securities issued will have a four-month hold period from the closing date.
Hemostemix ha annunciato un aggiornamento sulla sua seconda chiusura, aggiungendo un abbonamento di $50.000 per raggiungere un totale di proventi lordi di $2.725.981,77 attraverso l'emissione di 54.519.635 Unità. L'azienda ha pagato commissioni per trovatori di circa $28.820,64 ed ha emesso 576.413 opzioni per trovatori esercitabili a $0,05 per azione comune entro 24 mesi.
L'offerta include la partecipazione di alcuni membri del consiglio di amministrazione, costituendo una transazione tra parti correlate ai sensi del MI 61-101. L'azienda è esente da requisiti di valutazione formale e approvazione degli azionisti di minoranza in quanto il valore della transazione non supera il 25% della capitalizzazione di mercato. Tutti i titoli emessi avranno un periodo di lock-up di quattro mesi dalla data di chiusura.
Hemostemix ha anunciado una actualización sobre su segundo cierre, añadiendo una suscripción de $50,000 para alcanzar un total de ingresos brutos de $2,725,981.77 a través de la emisión de 54,519,635 Unidades. La empresa pagó comisiones a agentes de aproximadamente $28,820.64 y emitió 576,413 opciones para agentes que pueden ser ejecutadas a $0.05 por acción ordinaria en un plazo de 24 meses.
La oferta incluye la participación de directores de la empresa, constituyendo una transacción con partes relacionadas bajo la MI 61-101. La empresa está exenta de los requisitos de valoración formal y aprobación de accionistas minoritarios ya que el valor de la transacción no supera el 25% de la capitalización de mercado. Todos los valores emitidos tendrán un período de retención de cuatro meses a partir de la fecha de cierre.
Hemostemix는 두 번째 마감에 대한 업데이트를 발표했으며, 50,000달러의 구독을 추가하여 $2,725,981.77의 총 총수익을 달성했습니다. 이는 54,519,635 유닛 발행을 통해 이루어졌습니다. 회사는 약 28,820.64달러의 중개 수수료를 지불했으며, 24개월 이내에 주당 0.05달러로 행사할 수 있는 576,413개의 중개인 옵션을 발행했습니다.
이번 공모에는 회사 이사들의 참여가 포함되어 있으며, 이는 MI 61-101에 따른 관련 당사자 거래로 간주됩니다. 거래 가치가 시장 자본화의 25%를 초과하지 않기 때문에 회사는 공식 평가 및 소수 주주 승인 요건에서 면제됩니다. 발행된 모든 증권은 마감일로부터 4개월의 보유 기간이 있습니다.
Hemostemix a annoncé une mise à jour concernant sa deuxième clôture, ajoutant une souscription de 50 000 $ pour atteindre un produit brut total de 2 725 981,77 $ grâce à l'émission de 54 519 635 Unités. La société a payé des frais de recherche d'environ 28 820,64 $ et a émis 576 413 options de recherche pouvant être exercées à 0,05 $ par action ordinaire dans les 24 mois suivant la clôture.
L'offre comprend la participation des administrateurs de la société, constituant une transaction entre parties liées selon la MI 61-101. La société est exonérée des exigences de valorisation formelle et d'approbation des actionnaires minoritaires, car la valeur de la transaction ne dépasse pas 25 % de la capitalisation boursière. Tous les titres émis auront une période de restriction de quatre mois à compter de la date de clôture.
Hemostemix hat ein Update zu seinem zweiten Closing angekündigt und ein Abonnement über 50.000 $ hinzugefügt, um einen Gesamtbetrag an Bruttoeinnahmen von 2.725.981,77 $ durch die Ausgabe von 54.519.635 Einheiten zu erreichen. Das Unternehmen hat Findergebühren von etwa 28.820,64 $ bezahlt und 576.413 Finderoptionen ausgegeben, die innerhalb von 24 Monaten zu 0,05 $ pro Stammaktie ausgeübt werden können.
Das Angebot umfasst die Teilnahme von Unternehmensdirektoren, was eine Transaktion mit verbundenen Parteien gemäß MI 61-101 darstellt. Das Unternehmen ist von den Anforderungen an eine formale Bewertung und die Genehmigung durch Minderheitsaktionäre befreit, da der Transaktionswert 25 % der Marktkapitalisierung nicht übersteigt. Alle ausgegebenen Wertpapiere haben eine Haltefrist von vier Monaten ab Closing-Datum.
- Successful fundraising with gross proceeds of $2,725,981.77
- Additional subscription of $50,000 secured
- Share dilution through issuance of 54,519,635 new units
- Related party transaction with directors participating in the offering
Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is amending its closing documents to include an additional subscription of
In connection with the Offering, the Company paid eligible finders aggregate cash finder fees of approximately
For further details regarding the Company's Offering, please refer to the Company's News Releases dated October 11, October 31 and November 28, 2024. The Offering included subscribers under the investment dealer exemption. In accordance with the requirements of the investment dealer exemption, the Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
Certain directors of the Company participated in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSXV. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds
About Hemostemix
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit Hemostemix.com.
For further information, please contact:
Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com
PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232383
FAQ
How much did Hemostemix (HMTXF) raise in their latest offering?
What finder fees did Hemostemix (HMTXF) pay for the offering?